Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00833586 · ClinicalTrials.gov registry record · Phase 1
Terbinafine HCl 250 mg Tablet Under Fasting Conditions
A Phase 1 study, sponsored by Teva Pharmaceuticals USA.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT00833586: Completed Phase 1 study, sponsored by Teva Pharmaceuticals USA.
NCT00833586 is a Phase 1 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00833586, a Phase 1 study, has completed, sponsored by Teva Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the relative bioavailability of the test formulation of terbinafine tablets with an already marketed reference formulation Lamisil® (Novartis Pharmaceuticals), under fasted conditions in healthy, non-tobacco using male and female adult subjects.
Interventions
- DRUG Terbinafine HCl 250mg tablets
- DRUG Lamisil® 250 mg Tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2002-01 |
| Est. Completion | 2002-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00833586
The ClinicalTrials.gov registry entry for NCT00833586 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Pharmaceuticals USA, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Terbinafine HCl 250mg tablets is the first listed.
NCT00833586 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00833586 about?
NCT00833586 is a clinical study titled "Terbinafine HCl 250 mg Tablet Under Fasting Conditions". The purpose of this study is to evaluate the relative bioavailability of the test formulation of terbinafine tablets with an already marketed reference formulation Lamisil® (Novartis Pharmaceuticals), under fasted conditions in healthy, non-tobacco using male and female adult subjects.
What is the current status of trial NCT00833586?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2002-01. Estimated completion is 2002-01.
What interventions are being tested in trial NCT00833586?
The interventions under investigation include: Terbinafine HCl 250mg tablets (DRUG), Lamisil® 250 mg Tablets (DRUG).
Who is sponsoring clinical trial NCT00833586?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.